PNH
The FDA has accepted the BLA for crovalimab, an investigational treatment for paroxysmal nocturnal hemoglobinuria.
Iptacopan, a complement factor B inhibitor, was effective in patients with PNH with active hemolysis despite eculizumab use.
Take a look at these important studies relevant to anemia, venous thromboembolism, sickle cell disease, and PNH.
A study assessed survival and adverse events in patients with PNH treated with eculizumab.
Pegcetacoplan is a cost-effective alternative for the treatment of paroxysmal nocturnal hemoglobinuria.
The U.S. FDA has accepted a Biologics License Application for a novel drug to treat paroxysmal nocturnal hemoglobinuria.
Advertisement
Expert Interviews on Hematology
Advertisement
